Roivant Sciences/$ROIV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Roivant Sciences
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Ticker
$ROIV
Sector
Primary listing
Employees
750
Headquarters
Website
Roivant Sciences Metrics
BasicAdvanced
$13B
-
-$0.69
1.15
-
Price and volume
Market cap
$13B
Beta
1.15
52-week high
$18.86
52-week low
$8.73
Average daily volume
8.6M
Financial strength
Current ratio
40.537
Quick ratio
39.548
Long term debt to equity
1.875
Total debt to equity
2.07
Profitability
EBITDA (TTM)
-1,139.561
Gross margin (TTM)
-2,392.91%
Net profit margin (TTM)
-2,111.79%
Operating margin (TTM)
-4,961.40%
Effective tax rate (TTM)
-4.39%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-12.59%
Return on equity (TTM)
-18.15%
Valuation
Price to revenue (TTM)
576.075
Price to book
2.95
Price to tangible book (TTM)
2.95
Price to free cash flow (TTM)
-15.586
Free cash flow yield (TTM)
-6.42%
Free cash flow per share (TTM)
-1.207
Growth
Revenue change (TTM)
-35.86%
Earnings per share change (TTM)
-112.22%
3-year revenue growth (CAGR)
-23.49%
3-year earnings per share growth (CAGR)
-24.50%
What the Analysts think about Roivant Sciences
Analyst ratings (Buy, Hold, Sell) for Roivant Sciences stock.
Bulls say / Bears say
Roivant held $4.9 billion in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025, giving the company a solid liquidity runway towards profitability despite ongoing R&D investment (GlobeNewswire)
The company repurchased $1.3 billion of its shares by March 31, 2025—a 14% reduction in outstanding shares—and completed a $1.5 billion repurchase by June 30, 2025, launching an additional $500 million buyback program. This demonstrates disciplined capital allocation and support for EPS (GlobeNewswire; GlobeNewswire)
The VALOR Phase 3 study of brepocitinib in dermatomyositis is fully enrolled with topline data expected in the second half of 2025, and new registrational trials for IMVT-1402 in Graves' disease and Sjögren’s disease were started in June 2025, providing near-term clinical catalysts (GlobeNewswire; GlobeNewswire)
Q1 FY26 revenue dropped to $2.17 million from $7.99 million a year earlier, highlighting limited commercial-stage revenue diversity and a heavy dependence on near-term clinical milestones (GlobeNewswire)
For the fiscal year ended March 31, 2025, R&D expenses climbed by $110.5 million to $550.4 million and G&A expenses rose by $175.3 million—mainly due to share-based compensation—resulting in a $729.8 million loss from continuing operations, showing aggressive cash burn and growing operational losses (GlobeNewswire)
The expansion of LNP patent litigation against Moderna into international jurisdictions such as Canada, Japan, Switzerland, and the UPC, with summary judgment and jury trial phases ongoing into 2026, creates a legal overhang and possible significant litigation costs (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Roivant Sciences Financial Performance
Revenues and expenses
Roivant Sciences Earnings Performance
Company profitability
Roivant Sciences News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Roivant Sciences stock?
Roivant Sciences (ROIV) has a market cap of $13B as of October 28, 2025.
What is the P/E ratio for Roivant Sciences stock?
The price to earnings (P/E) ratio for Roivant Sciences (ROIV) stock is 0 as of October 28, 2025.
Does Roivant Sciences stock pay dividends?
No, Roivant Sciences (ROIV) stock does not pay dividends to its shareholders as of October 28, 2025.
When is the next Roivant Sciences dividend payment date?
Roivant Sciences (ROIV) stock does not pay dividends to its shareholders.
What is the beta indicator for Roivant Sciences?
Roivant Sciences (ROIV) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.